Halofuginone for liver fibrosis prevention and treatment?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1279, 2001-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is it worth increasing dose-density in cancer treatment?

Inpharma, Vol. 1, Iss. 1246, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

CXCR2: a target for pancreatic cancer treatment?

By Hertzer Kathleen M Donald Graham W Hines O Joe

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 6, 2013-09 ,pp. : 667-680

Informa Healthcare

Access to resources Recommend Favorite

Does alosetron have a place in IBS treatment?

Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Will patents hinder the progress made in HIV treatment?

Inpharma, Vol. 1, Iss. 1503, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Kidney disease a barrier to HIV treatment?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 543, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite